Related Experiment Video
Updated: Jun 29, 2025
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Genetic haute couture to block HIV-1 at front doors
1Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université de Montréal, Montreal, QC, Canada; Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada; CHUM Research Centre, 900 rue Saint-Denis, Tour Viger R, Room R09.416, Montreal, QC H2X 0A9, Canada.
Insights
This study introduces a novel gene editing approach to block HIV-1 entry by targeting both CCR5 and CXCR4 receptors. This strategy aims to prevent HIV-1 infection in hematopoietic stem and progenitor cells for a potential cure.
Area of Science:
- Immunology
- Virology
- Gene Therapy
Background:
- Chemokine receptors CCR5 and CXCR4 are critical entry points for HIV-1 into host cells.
- Targeting these receptors is a key strategy for developing HIV-1 cures.
- Autologous hematopoietic stem and progenitor cells (HSPCs) are a focus for cellular therapies.
Purpose of the Study:
- To propose a novel gene editing strategy for simultaneously blocking HIV-1 entry via CCR5 and CXCR4.
- To investigate the application of this strategy in autologous HSPCs.
Main Methods:
- Gene editing techniques were employed to modify HSPCs.
- The strategy targets the genetic pathways of both CCR5 and CXCR4 receptors.
Main Results:
- The proposed method aims to simultaneously inhibit CCR5- and CXCR4-mediated HIV-1 entry.
- Successful application in autologous HSPCs could prevent viral infection.
Conclusions:
- This gene editing strategy offers a potential new avenue for an HIV-1 cure.
- Simultaneous targeting of CCR5 and CXCR4 in HSPCs could provide robust protection against HIV-1 infection.
Abstract:
The chemokine receptors CCR5 and CXCR4 are "front doors" for HIV-1 infection in host cells, and their targeting represents a potential solution for a cure. Dudek et al.1 now propose a new gene editing strategy to simultaneously block CCR5- and CXCR4-mediated HIV-1 entry in autologous hematopoietic stem and progenitor cells (HSPCs).
